Gilead Sciences: stocks, financial statements

Disable ads for free
Dividends News
Favorites

It develops and implements innovative methods of treatment and prevention of severe diseases. The main research focuses on the fight against HIV and AIDS, cancer, hepatitis B and C, that is, specializes mainly in antiviral drugs. New types of treatments for Hematology, liver diseases, inflammatory and infectious diseases are also being produced, including various types of flu virus, including Harvoni and Sovaldi. In addition to the therapeutic direction, systems of specific care for patients with a severe form of the disease are being developed. Serial production of new drugs is concentrated in the regions where the problem of the spread of deadly diseases is most urgent - North and South Africa, Europe, and Asia.

The founder of the company, tried to «recruit» Warren Buffett as an investor and a member of the Board of Directors, but was unsuccessful. A year ago, The Times reported that this «American pharmaceutical firm used a controversial tax loophole to shift almost 20 billion euros of profits through an Irish legal entity in just two years.»

  • GILD Ticker
  • NASDAQ Exchange
  • 11,000 Employees
10 rated
  • $60.11, $-0.52 (-0.86%) Previous Close
  • 9,445,040 Previous Volume
  • $57.04 / $85.97 52 week low / high
  • -30.08% Percent off 52 week high
  • 2020-11-20 Updated
  • 4.44% Dividend Yield (trailing)
  • 4.53% Dividend Yield (forward)
  • 1,252,678,853 Public float
  • 1,253,530,000 Outstanding shares
  • 60.42 P/E
  • 75.53 B Market Cap
Disable ads for free

Financial statements — Gilead Sciences

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
19 ← 15 2019 2018 2017 2016 2015
Total Revenue
22B 22B 26B 30B 32B
Cost Of Revenue
4.7B 4.9B 4.5B 4.4B 4.1B
Gross Profit
18B 17B 22B 26B 28B
Research and Development
9.1B 4.2B 3.6B 4.3B 2.9B
Selling General and Admin
4.4B 4.1B 3.7B 3.3B 3.3B
Operating Expense
18B 13B 12B 12B 10B
Operating Income
4.3B 9.1B 14B 18B 22B
Other Income Expense Net
870M -1.3B -800M -1.3B 2M
EBIT
4.3B 9.1B 14B 18B 22B
Interest Income
1M 1.1B 1.1B 960M 690M
Pretax Income
5.2B 7.8B 14B 17B 22B
Income Tax
-200M 2.3B 8.9B 3.6B 3.6B
Minority Interest
-22M 5M 16M -13M -2M
Net Income
5.4B 5.5B 4.6B 14B 18B
Net Income Basic
5.4B 5.5B 4.6B 14B 18B
19 ← 15 2019 2018 2017 2016 2015
Current cash
12B 18B 7.6B 8.2B 13B
Short term investments
13B 13B 19B 3.7B 1.8B
Receivables
3.6B 3.3B 3.9B 4.5B 5.9B
Inventory
920M 810M 800M 1.6B 2B
Other current assets
1.1B 740M 1B 2.4B 2.3B
Current assets
30B 36B 32B 20B 25B
Long term investments
1.7B 1.6B 11B 20B 12B
Property plant equipment
5.2B 4B 3.3B 2.9B 2.3B
Goodwill
4.1B 4.1B 4.2B 1.2B 1.2B
Intangible assets
14B 16B 17B 9B 10B
Other assets
6.6B 2.4B 2.7B 2.6B 1.5B
Total assets
62B 64B 70B 57B 52B
Accounts payable
710M 790M 810M 1.2B 1.2B
Current long term debt
2.5B 2.7B 2.7B 980M
Other current liabilities
6.2B 6.9B 7.4B 8B 7.7B
Total current liabilities
9.8B 11B 12B 9.2B 9.9B
Long term debt
23B 25B 31B 26B 21B
Other liabilities
6.5B 7B 7.4B 2B 1.6B
Minority Interest
-22M 5M 16M -13M -2M
Total Liabilities
39B 42B 50B 38B 33B
Common stock
1.3B 1.3B 1.3B 1.3B 1.4B
Retained earning
19B 19B 19B 18B 18B
Treasury stock
6.5M 9.1M 8.3M 9M 8.8M
Capital surplus
3.1B 2.3B 1.3B 450M 440M
Shareholder equity
23B 21B 20B 19B 19B
Net tangible assets
-5.7B -7.6B -8.8B 4.7B 3.9B
19 ← 15 2019 2018 2017 2016 2015
Net Income
5.4B 5.5B 4.6B 14B 18B
Depreciation
1.4B 1.4B 1.3B 1.2B 1.1B
Changes in receivables
-260M 520M 660M 1.3B
Changes in inventories
-95M -310M -250M -490M -860M
Cash change
-6.3B 10B -640M -4.6B 2.8B
Cash flow
9.1B 8.4B 12B 17B 20B
Capital expenditures
-830M -920M -590M -750M -750M
Investments
-2.3B 15B -5.1B -11B -12B
Investing activity other
-4.7B
Total investing cash flows
-7.8B 14B -16B -12B -12B
Dividends paid
-3.2B -3B -2.7B -2.5B -1.9B
Net borrowings
-2.8B -6.3B 7.2B 4.3B 9.7B
Other financing cash flows
-120M -490M -330M -370M -3.1B
Cash flow financing
-7.6B -12B 3.4B -9.3B -5B
Exchange rate effect
-2M -85M 140M 41M -67M
Disable ads for free
Disable ads for free